For CDKN2A PV carriers, these guidelines recommend initiation of surveillance 10 years earlier than the earliest age of pancreatic cancer diagnosis in the family, or at age 40, whichever is earlier. The gene discussed is CDKN2A; the disease is familial pancreatic carcinoma.